Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook
Question
Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook
Direct answer
Abbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex. — bullish pressure on ABT.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-13
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook”, revision 1, evidence through 2026-10-13. https://marketontology.com/catalysts/2026-10-13/abbott-and-abbvie-gain-over-1-6-outperforming-s-p-on-strong-q3-growth-outlook-5de1e0
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ABT | ▲Bull | 1–4 weeks | Catalyst Driven | 72 |
| ABBV | ▲Bull | 1–4 weeks | Catalyst Driven | 71 |
Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook
Abbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex. — bullish pressure on ABT.
Abbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex.
- SummaryAbbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex.
- ABTDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- ABT closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ABT price vs. pre-event level
- ABT volume vs. 20-day average
Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth Outlook
Abbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex. — bullish pressure on ABBV.
Abbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex.
- SummaryAbbott Laboratories advanced 2.23% to $101.82, outpacing the S&P 500's 0.06% daily dip. The company is set to report third-quarter earnings on October 21, 2026, where consensus forecasts project a 9.23% year-over-year increase in EPS to $1.42 and a 13.52% expansion in revenue to $12.91 billion. AbbVie rose 1.65% to $281.04, building on a 7.53% one-month gain. Analysts project AbbVie's October 30 earnings release to reflect a 104.3% surge in EPS alongside a 10.01% top-line increase, providing fundamental support to the large-cap pharmaceutical complex.
- ABBVDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- ABBV closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ABBV price vs. pre-event level
- ABBV volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings ReleaseABT
- 2026-10-13Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line GrowthABT IHI XLV+2.53%
- 2026-10-13Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42ABT
- 2026-10-13Abbott Sets Q3 2026 Earnings Release for October 21 with $12.91B Revenue ForecastABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.